Akero Therapeutics (NASDAQ:AKRO) Azioni

AKERO THERAPEUTICS INC

Akero Therapeutics

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Akero Therapeutics Inc

Akropolis

Liberty Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>) has outperformed the market over the past 5 years by 4.05% on an annualized basis producing an average annual return of 19.08%. Currently, Liberty Energy has a market capitalization of $1.94 billion. 
Buying $100 In LBRT: If an investor had bought $100 of LBRT stock 5 years ago, it would be worth $220.85 today based on a price of $11.97 for LBRT at the time of writing.
<h3>Liberty Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747697411_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

LBRT

Here's How Much You Would Have Made Owning Liberty Energy Stock In The Last 5 Years

Kinsale Cap Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNSL#NYSE">KNSL</a>) has outperformed the market over the past 5 years by 10.75% on an annualized basis producing an average annual return of 25.77%. Currently, Kinsale Cap Gr has a market capitalization of $11.01 billion. 
Buying $100 In KNSL: If an investor had bought $100 of KNSL stock 5 years ago, it would be worth $326.40 today based on a price of $472.20 for KNSL at the time of writing.
<h3>Kinsale Cap Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747696513_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KNSL

$100 Invested In Kinsale Cap Gr 5 Years Ago Would Be Worth This Much Today

Darling Ingredients (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAR#NYSE">DAR</a>) and Tessenderlo Group disrupted the enormously profitable health, wellness and nutrition industry this week, <a href="https://www.benzinga.com/pressreleases/25/05/b45340702/darling-ingredients-and-tessenderlo-group-agree-to-form-new-company-to-accelerate-growth-in-attrac">announcing an agreement</a> to merge the collagen and gelatin units of their waste recovery operations into the newly formed Nextiva. Darling already produces 30% of the world's collagen supply, while the joint venture could generate up to $1.5 billion in revenue in its first year of operation.&nbsp;
Nextiva will sit in collagen's sweet spot, with industry growth forecast to rise 9.5% annually, reaching over $14 billion in 2033. This biological gold is extracted from animal skin, tendon, cartilage and bone that waste recovery companies used to throw away as useless byproduct. Its popularity in cosmetics, joint health, supplements, biomaterials and pharmaceuticals has exploded in the last decade, with anti-aging and skin health benefits touted by Jennifer Aniston, Kate Hudson, Kourtney Kardashian and other celebrities.
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
Texas-based Darling has struggled in the last two years, with annual revenue dropping from $6.79 billion in fiscal 2023 to $5.22 billion in fiscal 2024. This marked the first revenue downturn for the S&amp;P Mid Cap 400 component since 2019. The hookup is a strategic move to respond to Wall Street about declining performance and regrow earnings by leveraging its leadership in the profitable animal byproducts segment.&nbsp;
Top tier investment firms including Piper Sandler, <a href="https://www.benzinga.com/markets/25/04/45039081/td-cowen-says-twenty-one-reflects-most-meaningful-validation-of-strategys-bitcoin-treasury-operation">TD Cowen</a>, and UBS cover Darling stock but have yet to issue research reports on this week's news. Clearly, their endorsements will help the deal proceed without roadblocks. In late April, Jason Gabelman at TD Cowen lowered his Darling price target from $37 to $34, pointing to an inconsistent track record on guidance. His ‘take' on the new venture will be watched closely by Wall Street.
Chairman and CEO Randall C. Stuewe touted the venture, saying, &#8220;Collagen has represented the fastest-growing area of <a href="https://www.benzinga.com/insights/earnings/25/04/44962097/what-to-expect-from-darling-ingredientss-earnings">Darling Ingredients</a>&#8216; food segment business over the past several years.&#8221; He added that the joint venture will provide a "platform for accelerated product development and growth" and create an opportunity to "unlock significant shareholder value." Darling will own 85% of Nextiva, according to the release, while its Brussels partner holds the balance. Together they intend to operate 23 facilities on four continents, producing about 200,000 tons of collagen and gelatin in the first year.&nbsp;
Trending: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a>
The hookup is not expected to close until 2026. The initial press release describes the venture as a noncash transaction that combines assets and capabilities, but negotiations are continuing, and no definitive documentation has been sign by principals. However, the ownership ratio between the much larger Darling and its smaller partner appears locked-in and there are no obvious red flags to the startup currently.
Nextiva will also require regulatory approval in the U.S. and European Union, which might face unexpected hurdles, given current political tensions. Meanwhile, collagen use remains unregulated and somewhat controversial, <a href="https://www.health.harvard.edu/blog/considering-collagen-drinks-and-supplements-202304122911">with critics noting the refined product</a> used in supplements breaks down when ingested, rather than rebuilding our naturally produced substance. They also point to the corruptive influence of marketing hype, driven by celebrities owning companies benefiting from collagen use.
Regardless, both critics and advocates consider collagen use to be safe and our beauty-obsessed culture has a long history of chasing the latest ‘Fountain of Youth', regardless of cost. This bodes well for Darling and Tessenderlo's profit growth in coming years. And, given their giant industry footprint, they could strongly influence worldwide supply and pricing in coming decades.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a></li>
<li>The team behind $6B+ in licensing deals is now building the next billion-dollar IP empire — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">invest early at $2.25/share.</a></li>
</ul>
Image: Shutterstock

New Wellness JV Nexida Aims to Tackle Aging—And They're Backed by a Third of the World's Collagen Supply

Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) has outperformed the market over the past 5 years by 28.48% on an annualized basis producing an average annual return of 43.51%. Currently, Brinker International has a market capitalization of $6.63 billion. 
Buying $1000 In EAT: If an investor had bought $1000 of EAT stock 5 years ago, it would be worth $6,083.67 today based on a price of $149.05 for EAT at the time of writing.
<h3>Brinker International's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747695674_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Brinker International Stock In The Last 5 Years

Taiwan Minister of Economic Affairs J.W. Kuo said the U.S. tariffs did not <a href="https://www.benzinga.com/topic/taiwan" target="_blank" rel="noreferrer noopener">bother Taiwanese manufacturers</a>, highlighting its leverages, notably its semiconductor ecosystem.
Kuo emphasized the U.S. dependence on Taiwan to boost its microchip manufacturing capacities, the Taipei Times <a href="https://www.taipeitimes.com/News/biz/archives/2025/05/19/2003837104" target="_blank" rel="noreferrer noopener">reported</a> on Monday, citing the minister&#8217;s interview.
Kuo expects Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) to maintain its moat over the next decade citing any tariff upsurge would primarily affect US customers instead of the foundry.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45411148/taiwan-semiconductor-commits-15-billion-to-chip-expansion-approves-dividend-amid-rising-global-demand" rel="noreferrer noopener">Taiwan Semiconductor Commits $15 Billion To Chip Expansion, Approves Dividend</a>
Kup expects Samsung Electronics Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>) to bear the maximum brunt of the tariff policies due to its lack of advanced semiconductor production capacity.
Taiwan has submitted a position paper under Section 232 of the U.S. Trade Expansion Act to define the &#8220;complementary relationship&#8221; between Taiwan and the U.S. in terms of trade and technology and adopted policies to prevent illegal transshipments, Kuo told the Taipei Times.
Trump administration on April 2 announced that it would slap &#8220;reciprocal&#8221; tariffs on global trading partners of 32%, 25%, and 24% tariffs on goods from Taiwan, South Korea, and Japan to encourage companies to manufacture their products in the US. However, President Trump recently paused the policy for 90 days.
Reportedly, Taiwan Semiconductor <a target="_blank" href="https://www.benzinga.com/markets/asia/25/05/45466444/to-serve-exploding-ai-chip-demand-taiwan-semiconductor-plans-9-advanced-factories" rel="noreferrer noopener">will construct nine</a> new&nbsp;advanced wafer manufacturing&nbsp;and packaging factories by 2025.
It plans to build nine new factories, including eight wafer fabrication plants and one advanced chip packaging factory.
The contract chipmaker expects to see 60% year-over-year growth in chip shipments with the 3-nanometer process.
Price Action: TSM stock closed at $193.50 on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/media/25/05/45456613/intel-cfo-says-new-chip-output-for-clients-will-be-minimal-eyes-foundry-breakeven-by-2027" target="_blank" rel="noreferrer noopener">Intel CFO Says New Chip Output For Clients Will Be Minimal, Eyes Foundry Breakeven By 2027</a></li>
</ul>
Photo Courtesy Jack Hong via Shutterstock

Asia

Government

Regulations

Tech

Media

SSNLF

Taiwan Minister Shrugs Off US Tariffs, Says Taiwan Semiconductor Will Thrive While Samsung Takes The Hit

JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) CEO Jamie Dimon delivered a sobering assessment of the economic landscape at the bank's annual investor day on Monday. 
The head of the nation's largest bank warned that markets are displaying an "extraordinary amount of complacency" in the face of mounting risks from tariffs, record U.S. deficits <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45497403/is-the-dollars-global-reserve-role-at-risk-after-moodys-downgrade">and geopolitical tensions.</a>
The Details: Dimon cautioned that investors and central banks are underestimating the potential for persistent inflation and even stagflation. In fact, he said the odds of a stagflationary scenario are "roughly double" what people think, <a href="https://www.cnbc.com/2025/05/19/trump-tariffs-jpmorgan-chase-ceo-jamie-dimon.html">according</a> to CNBC. 
Read Next: <a href="https://www.benzinga.com/news/large-cap/25/05/45499101/big-short-legend-michael-burry-bets-big-on-lipstick-index-is-he-bracing-for-a-recession?utm_source=article">&#8216;Big Short&#8217; Legend Michael Burry Bets Big On Lipstick Index: Is He Bracing For A Recession?</a>
He noted that the full economic impact of tariffs has yet to be felt and predicted that earnings forecasts for S&amp;P 500 companies could fall to zero growth within six months, down from about 12% at the start of the year.&nbsp;
"I think earnings estimates will come down, which means PE will come down," Dimon said, signaling the potential for further declines in stock prices if corporate profits falter.
The JPMorgan CEO also pointed to the U.S. budget deficit after Moody's downgraded the country's<a href="https://www.benzinga.com/news/econ-s/25/05/45479078/moodys-downgrades-us-credit-rating-over-debt-deficit-concerns"> credit rating</a> last Friday, citing concerns over a sustained increase in government debt and interest payment ratios.&nbsp;&nbsp;
"We have huge deficits; we have what I consider almost complacent central banks," Dimon said.
"You all think they can manage all this. I don't think they can," he added.
Despite these headwinds, JPMorgan reaffirmed its 2025 expense and net interest income guidance, projecting $90 billion in core lending revenue with an additional $4.5 billion possible from trading, depending on market conditions.
However, the bank expects investment banking fees to drop by a "mid-teens" percentage in the second quarter compared to last year, reflecting a slowdown in dealmaking as corporate clients adopt a cautious, wait-and-see approach.
Dimon also addressed the bank's succession plans and reiterated his intention to step down as CEO within the next few years, but not offering a more specific timeline.&nbsp;
"If I'm here for four more years, and maybe two more [as executive chairman]," Dimon said, "that's a long time.
Read Also:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45506863/trumps-big-beautiful-bill-advances-heres-who-wins-and-loses?utm_source=articleShare">Trump&#8217;s &#8216;Big Beautiful Bill&#8217; Advances: Here&#8217;s Who Wins And Loses&nbsp;</a></li>
</ul>
Image:&nbsp;Shutterstock

Management

JPMorgan CEO Jamie Dimon Warns 'Huge Deficits,' 'Complacent Central Banks' Could Lead To Stagflation

Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) has outperformed the market over the past 10 years by 18.83% on an annualized basis producing an average annual return of 29.77%. Currently, Netflix has a market capitalization of $506.55 billion. 
Buying $100 In NFLX: If an investor had bought $100 of NFLX stock 10 years ago, it would be worth $1,354.25 today based on a price of $1190.29 for NFLX at the time of writing.
<h3>Netflix's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747694713_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NFLX

Here's How Much $100 Invested In Netflix 10 Years Ago Would Be Worth Today

Trip.com Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>) reported unaudited results for the first quarter after the market close on Monday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/05/n45507946/trip-com-group-limited-reports-unaudited-first-quarter-of-2025-financial-results">of the report</a>.
Q1 Earnings: Trip.com reported first-quarter revenue of $1.91 billion, in line with analyst estimates, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The travel service provider reported first-quarter adjusted earnings per ADS of 82 cents, missing estimates of 86 cents.
Total revenue was up 16% year-over-year. Here&#8217;s a breakdown of revenue growth by category:
<ul class="wp-block-list">
<li>Accommodation reservation revenue: up 23%</li>
</ul>
<ul class="wp-block-list">
<li>Transportation ticketing revenue: up 8%</li>
</ul>
<ul class="wp-block-list">
<li>Packaged-tour revenue: up 7%</li>
</ul>
<ul class="wp-block-list">
<li>Corporate travel revenue: up 12%</li>
</ul>
Trip.com ended the first quarter with $12.8 billion in cash, cash equivalents, restricted cash and short-term investments.
&#8220;We are pleased to see a strong start to 2025. As travel becomes an increasingly integral part of everyday life, we remain committed to meeting the evolving needs of travelers through innovative, localized and customer-centric solutions. This positions us well to sustain growth momentum and deliver lasting value to our customers, partners, and shareholders,&#8221; said Jane Sun, CEO of Trip.com
Trip.com&#8217;s management team will further discuss the quarter on a conference call with investors and analysts at 8 p.m. ET. The company also scheduled a shareholder meeting for June 30.
TCOM Price Action: <a href="http://benzinga.com/quote/tcom">Trip.com shares</a> were down about 2% year-to-date heading into the print. The stock was down 1.79% after-hours, trading at $65.90 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/management/25/05/45463946/airbnb-ceo-brian-chesky-reveals-why-he-doesnt-do-emails-and-early-morning-meetings-says-silicon-valley-founders-dont-need-to-be-miserable">Airbnb CEO Brian Chesky Reveals Why He Doesn&#8217;t Do Emails And Early Morning Meetings, Says Silicon-Valley Founders Don&#8217;t Need To Be &#8216;Miserable&#8217;</a></li>
</ul>
Photo: Shutterstock.

Earnings

Travel

Global

After-Hours Center

Movers

TCOM

Trip.com Shares Slide After Travel Service Provider Misses Q1 Earnings Estimates

Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) has outperformed the market over the past 20 years by 18.52% on an annualized basis producing an average annual return of 26.85%. Currently, Amazon.com has a market capitalization of $2.17 trillion. 
Buying $100 In AMZN: If an investor had bought $100 of AMZN stock 20 years ago, it would be worth $11,697.02 today based on a price of $206.00 for AMZN at the time of writing.
<h3>Amazon.com's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747693813_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMZN

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

The late Kobe Bryant was a fierce competitor on the court and an equally skilled businessman off it.&nbsp;
According to <a href="https://www.forbes.com/profile/kobe-bryant/">Forbes</a>, He amassed a $600 million fortune before his tragic death. However, Rome wasn't built in a day, and neither was Bryant's empire. During an interview before his passing, Bryant credited an<a href="https://www.benzinga.com/money/how-to-build-a-stock-portfolio"> investment</a> he made in himself as a teenager with setting him up for the success he enjoyed on and off the court.
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
Bryant's competitive streak and unflinching confidence were the signature traits of his career. Those character traits may have felt natural when Bryant burst onto the stage in 1996, but nothing could be further from the truth. Bryant's path to the NBA was full of unorthodox turns and uncomfortable situations. It started with his return to the U.S. at age 13.
Bryant's father, Joe, was a professional basketball player who finished his career playing in Italy. That necessitated taking the then five-year-old Bryant along for the ride, and America felt like a foreign country when he returned eight years later. Bryant's 2015 Documentary,<a href="https://youtu.be/8dga5amhKnQ?si=WLVRg8YEG1-8o3q5&amp;t=1199"> </a>"<a href="https://youtu.be/8dga5amhKnQ?si=WLVRg8YEG1-8o3q5&amp;t=1199">Kobe Bryant's Muse</a>" shed light on this difficult time of his young life.
During the documentary, Bryant recounts, "I didn't understand the slang. I was a little Italian boy. I didn't understand the fashion. I couldn't spell, and the teacher told my mother I was probably dyslexic. I didn't know anybody. Sitting at a lunch table all by myself, no friends. I was upset that I had moved. I had all this resentment and anger inside of me that I hadn't really let out."
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a>
This kind of experience makes some people turn inward or lose their self-confidence during their formative years, but Bryant learned to embrace being an outsider. He came to see it as a strength and not a weakness. Bryant also found a place to channel his anger: basketball.
&nbsp;"It was never viewed as, ‘I'm going to control [my anger],'&#8221; <a href="https://www.youtube.com/watch?v=8dga5amhKnQ">Bryant</a> said in "<a href="https://www.youtube.com/watch?v=8dga5amhKnQ">Muse</a>". "I'm just going to push it to the side and then use it to my benefit for what it is that I love doing, which is playing the game. Once I discovered that, everything about the game changed." It may not have felt like it at the time, but this was the beginning of Bryant developing his now-infamous "mamba mentality."&nbsp;
Not all investments are monetary. Taking the time to figure out how to handle adversity and function in uncomfortable situations is one of the best investments anyone can make in themselves. The same can be said for embracing the fact that you are an outsider. Bryant would go on to be an outsider in many situations, and his early investment in mental toughness paid off almost every time.
See Also: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a>
He entered the Los Angeles Lakers locker room as an 18-year-old who never attended college. Both of these things made him very different from his teammates, who were older and all attended college before playing professional basketball. Bryant was so young that he couldn't even go to bars with his teammates until he'd been in the league for three years.
He didn't sulk or wait around for greatness to come. Bryant used the solitude to invest in himself and hone his skills. It's the same discipline he approached in his career outside of basketball. That's how Bryant won an Academy Award for Best Animated Short Film with his movie, "Dear Basketball." There is a valuable lesson for investors to learn from this story.
&nbsp;Get comfortable with being uncomfortable because learning to fight through that adversity will help you grow by leaps and bounds. Bryant's initial unease around his NBA peers eventually faded, and he became one of the game's all-time greats. Keep this in mind when you find yourself feeling apprehensive about talking to investment advisors or<a href="https://www.benzinga.com/money/how-long-to-build-wealth-in-real-estate"> wealth-building</a>.
Read Next:
<ul class="wp-block-list">
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
Image: Shutterstock

Personal Finance

How The Late Kobe Bryant Began Building His $600 Million Fortune When He Was Only 13

General Motors Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) has announced the end of vehicle exports from the U.S. to China, a decision communicated to employees and dealers of its China export business. 
This move comes amid ongoing U.S.-China trade discussions, particularly concerning tariffs and broader economic conditions, according<a href="https://www.reuters.com/business/autos-transportation/gm-stop-exporting-vehicles-us-china-company-says-2025-05-19/?utm_source=chatgpt.com"> to</a> Reuters.
GM&#8217;s exports to China were facilitated through its Durant Guild premium import division, which accounted for less than 0.1% of its total sales in the Chinese market. The company cited significant changes in economic conditions as the reason for restructuring the Durant Guild and optimizing GM China&#8217;s operations. This follows a similar decision by GM&#8217;s competitor, Ford Motor Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), which halted its exports to China in April, <a href="https://www.reuters.com/business/autos-transportation/gm-stop-exporting-vehicles-us-china-company-says-2025-05-19/?utm_source=chatgpt.com">said</a> Reuters.
The broader context of these decisions includes significant financial challenges for GM in China. In December 2024, GM recorded a $5 billion charge against its Chinese operations due to increasing competition and market challenges. This included a write-down of up to $2.9 billion in its Chinese joint venture and $2.7 billion in restructuring charges. The restructuring efforts involve plant closures and portfolio optimization to counter market challenges, <a href="https://www.thetimes.com/business-money/companies/article/general-motors-takes-5bn-charge-against-operation-in-china-zf8g9d9j8?utm_source=chatgpt.com&amp;region=global">according</a> to The Times.
As part of its restructuring, GM is closing its plant in Shenyang, China, which produced Buick GL8 minivans and Chevrolet Tracker SUVs. This decision is in response to intense competition from local manufacturers and is part of a broader strategy to focus on premium vehicles under the Cadillac and Buick brands, along with its premium import business, <a href="https://www.reuters.com/business/autos-transportation/gm-closing-plant-china-part-restructuring-2025-02-14/?utm_source=chatgpt.com">said</a> Reuters.
These strategic shifts by GM and Ford highlight the challenges faced by U.S. automakers in the Chinese market, including high tariffs and increasing competition from local manufacturers, particularly in the electric vehicle sector. Both companies are adapting their operations to navigate these challenges and optimize their global strategies.
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45505333/investors-piled-into-long-term-treasury-etfs-ahead-of-moodys-downgrade-will-confidence-hold"> • Investors Piled Into Long-Term Treasury ETFs Ahead Of Moody&#8217;s Downgrade: Will Confidence Hold?</a>
Photo: Shutterstock

GM Announces The End Of Car Exports To China

Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) has outperformed the market over the past 5 years by 13.41% on an annualized basis producing an average annual return of 28.44%. Currently, Spotify Technology has a market capitalization of $136.26 billion. 
Buying $1000 In SPOT: If an investor had bought $1000 of SPOT stock 5 years ago, it would be worth $3,448.27 today based on a price of $664.50 for SPOT at the time of writing.
<h3>Spotify Technology's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747692919_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SPOT

$1000 Invested In Spotify Technology 5 Years Ago Would Be Worth This Much Today

American Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREC#NASDAQ">AREC</a>) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.12) by 100 percent. This is a 60 percent decrease over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $49.68 thousand which missed the analyst consensus estimate of $1.30 million by 96.18 percent. This is a 25.19 percent decrease over sales of $66.40 thousand the same period last year.

Earnings Misses

AREC

American Res Q4 EPS $(0.24) Misses $(0.12) Estimate, Sales $49.68K Miss $1.30M Estimate

<a href="https://asia.nikkei.com/Business/Finance/Mizuho-and-Mercer-to-team-up-to-offer-asset-management-services">https://asia.nikkei.com/Business/Finance/Mizuho-and-Mercer-to-team-up-to-offer-asset-management-services</a>

General

'Mizuho and Mercer to team up to offer asset management services'- Nikkei Asia

Qifu Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QFIN#NASDAQ">QFIN</a>) .

Guidance

QFIN

Qifu Technology forecasts Q2 2025 net income of RMB1.65B -1.75B and non-GAAP net income of RMB1.75B-1.85B.

Qifu Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QFIN#NASDAQ">QFIN</a>) reported quarterly earnings of $1.86 per share which beat the analyst consensus estimate of $1.72 by 8.14 percent. This is a 77.14 percent increase over earnings of $1.05 per share from the same period last year. The company reported quarterly sales of $646.40 million which beat the analyst consensus estimate of $615.60 million by 5.00 percent. This is a 12.38 percent increase over sales of $575.21 million the same period last year.

Earnings Beats

Qifu Technology Q1 Adj. EPS $1.86 Beats $1.72 Estimate, Sales $646.40M Beat $615.60M Estimate

Trip.com Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>) reported quarterly earnings of $0.82 per share which missed the analyst consensus estimate of $0.86 by 4.65 percent. This is a 1.2 percent decrease over earnings of $0.83 per share from the same period last year. The company reported quarterly sales of $1.91 billion which met the analyst consensus estimate. This is a 15.69 percent increase over sales of $1.65 billion the same period last year.

Trip.com Group Q1 Adj. EPS $0.82 Misses $0.86 Estimate, Sales $1.91B Inline

11 analysts have shared their evaluations of WR Berkley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $70.55, a high estimate of $80.00, and a low estimate of $62.00. Observing a 8.39% increase, the current average has risen from the previous average price target of $65.09. 
<img src="https://www.benzinga.com/files/images/story/2025/1747692089_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of WR Berkley by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$75.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Bob Huang</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$75.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Brian Meredith</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$78.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$65.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$62.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Yaron Kinar</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$66.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$62.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$69.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Mark Hughes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Joshua Shanker</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$74.00</td>
<td>$73.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to WR Berkley. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of WR Berkley compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of WR Berkley's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into WR Berkley's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WRB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on WR Berkley analyst ratings.</a>
<h2>Unveiling the Story Behind WR Berkley</h2>
W.R. Berkley is an insurance holding company with a host of subsidiaries that primarily underwrite commercial casualty insurance. The firm specializes in niche products that include various excess and surplus lines, workers' compensation insurance, self-insurance consulting, reinsurance, and regional commercial lines for small and midsize businesses.
<h3>WR Berkley's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3M period, WR Berkley showcased positive performance, achieving a revenue growth rate of 7.89% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: WR Berkley's net margin excels beyond industry benchmarks, reaching 11.84%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): WR Berkley's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.82%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): WR Berkley's ROA stands out, surpassing industry averages. With an impressive ROA of 1.02%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: WR Berkley's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.32, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Expert Outlook: WR Berkley Through The Eyes Of 11 Analysts

In the last three months, 11 analysts have published ratings on Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>), offering a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Travelers Companies, presenting an average target of $273.64, a high estimate of $296.00, and a low estimate of $247.00. Witnessing a positive shift, the current average has risen by 3.01% from the previous average price target of $265.64.
<img src="https://www.benzinga.com/files/images/story/2025/1747692078_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Travelers Companies. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Phillips</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$269.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$260.00</td>
<td>$247.00</td>
</tr>
<tr>
<td>David Motemaden</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$296.00</td>
<td>$288.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$290.00</td>
<td>$274.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$280.00</td>
<td>$287.00</td>
</tr>
<tr>
<td>Yaron Kinar</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$270.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Brian Meredith</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$267.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$274.00</td>
<td>$286.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$247.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Underweight</td>
<td>$271.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$286.00</td>
<td>$275.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Travelers Companies. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Travelers Companies compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Travelers Companies's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Travelers Companies's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TRV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Travelers Companies analyst ratings.</a>
<h2>All You Need to Know About Travelers Companies</h2>
Travelers offers a broad product range and participates in both commercial and personal insurance lines. Its commercial operations offer a variety of coverage types for companies of any size but concentrate on serving midsize businesses. Its personal lines are roughly evenly split between auto and homeowners insurance.
<h3>Key Indicators: Travelers Companies's Financial Health</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Travelers Companies's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 5.18%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Travelers Companies's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 3.32%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.4%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Travelers Companies's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.29%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.28, Travelers Companies adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 11 Analysts Discuss Travelers Companies Stock

Analysts' ratings for JM Smucker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJM#NYSE">SJM</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for JM Smucker, revealing an average target of $124.8, a high estimate of $134.00, and a low estimate of $119.00. Observing a 0.1% increase, the current average has risen from the previous average price target of $124.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1747692069_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of JM Smucker among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas Palmer</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$128.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Peter Grom</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$134.00</td>
<td>-</td>
</tr>
<tr>
<td>Megan Alexander</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$123.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Holland</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$120.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Andrew Lazar</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$119.00</td>
<td>$123.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to JM Smucker. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of JM Smucker compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of JM Smucker's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SJM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on JM Smucker analyst ratings.</a>
<h2>Delving into JM Smucker's Background</h2>
J.M. Smucker is a packaged food company that primarily sells through the US retail channel (78% of fiscal 2024 revenue came through its retail pet foods, coffee, and frozen handheld/spreads segments), with the remaining share consisting of Hostess and international (primarily Canada). Retail coffee is its largest category (33% of sales) with brands Folgers and Dunkin'. Pet foods (22% of sales) holds leading brands like Milk-Bone and Meow Mix. Of its remaining, approximately 22% comes from consumer foods, primarily peanut butter and jelly, through brands Jif and Smucker's. The company acquired Hostess Brands in fiscal 2024 to boost its snack and convenience store presence.
<h3>Breaking Down JM Smucker's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3M period, JM Smucker faced challenges, resulting in a decline of approximately -1.94% in revenue growth as of 31 January, 2025. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: JM Smucker's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -30.3%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): JM Smucker's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -9.11%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -3.45%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.15, caution is advised due to increased financial risk.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For JM Smucker's Future

Legal

Press Releases

Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is Investigating Claims on Your Behalf

INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm

Health Care

Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025

Long-Term Shareholders Have Rights – If You Hold Akero Therapeutics, Inc. (NASDAQ: AKRO); Integra Lifesciences Holdings Corporation (NASDAQ: IART); Mercury Systems, Inc. (NASDAQ: MRCY); or Virtu Financial Inc. (NASDAQ: VIRT), Contact Grabar Law Office

Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference

Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025

Comments

Akero Therapeutics

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO